| 1. |
Mao, S.-Y., Javois, L. C., and Kent, U. M. (1999) Overview of antibody use in immunocytochemistry, in Methods in Molecular Medicine, vol 115: Immunocytochemical Methods and Protocols (Javois, J. C., ed), Humana Press, Totowa, pp. 3–10.
|
| |
| 2. |
Sternberger, L. A. (1979) Immunocytochemistry, 2nd ed. Wiley, New York.
|
| |
| 3. |
Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994) Mutations in the p53 tumor suppressor gene: clues
to cancer etiology and molecular pathogenesis. Cancer Res.
54, 4855–4878.
|
| |
| 4. |
Lutzker, S. G. and Levine, A. J. (1996) A functionally inactive p53 protein in teratocarcinoma cells is activated by either
DNA damage or cellular differentiation. Nat. Med.
2, 804–810.
|
| |
| 5. |
Riou, G., Barrois, M., Prost, S., Terrier, M. J., Theodore, C., and Levine, A. J. (1995) The p53 and mdm-2 genes in human
testicular germ-cell tumors. Mol. Carcinog.
12, 124–131
|
| |
| 6. |
Murty, V. V., Bosl, G. J., Houldsworth, J., et al. (1994) Allelic loss and somatic differentiation in human male germ cell
tumors. Oncogene
9, 2245–2251.
|
| |
| 7. |
Peng, H. Q., Hogg, D., Malkin, D., et al. (1993) Mutations of the p53 gene do not occur in testis cancer. Cancer Res.
53, 3574–3578.
|
| |
| 8. |
Schenkman, N. S., Sesterhenn, I. A., Washington, L., et al. (1995) Increased p53 protein does not correlate with mutations
in microdissected human testicular germ cell tumors. J. Urol.
154, 617–621.
|
| |
| 9. |
Xu, L., Chen, Y. T., Huvos, A. G., et al. (1994) Overexpression of p53 in squamous cell carcinomas of head and neck without
apparent gene mutations. Diagn. Mol. Pathol.
3, 83–92.
|
| |
| 10. |
Kennedy, S. M., MacGeogh, C., Jaffe, R., and Spurr, N. K. (1994) Overexpression of the oncoprotein p53 in primary hepatic
tumor of childhood does not correlate with the gene mutations. Hum. Pathol.
25, 438–442.
|
| |
| 11. |
Ambros, R. A., Ross, J. F., Kallakury, B. V. S., et al. (1995) p53 gene status in endometrial carcinomas showing diffuse positivity
for p53 protein by immunohistochemical analysis. Mod. Pathol.
8, 441–445.
|
| |
| 12. |
King, S. A., Adas, A. A., LiVolsi, V. A., et al. (1995) Expression and mutation analysis of the p53 gene in uterine papillary
serous carcinoma. Cancer
75, 2700–2705.
|
| |
| 13. |
Marchenko, N. D. and Moll, U. M. (1997) Nuclear overexpression of p53 protein does not correlate with gene mutation in primary
peritoneal carcinoma. Hum. Pathol.
28, 1002–1006.
|
| |
| 14. |
Zhang, W., Hu, G., Estey, E., Hester, J., and Deisseroth, A. (1992) Altered conformation of the p53 protein in myeloid leukemia
cells and mitogen-stimulated normal blood cells. Oncogene
7, 1645–1647.
|
| |
| 15. |
Moll, U. M., LaQuaglia, M., Benard, J., and Riou, G. (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated
neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA
92, 4407–4711.
|
| |
| 16. |
Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Mol, U. M., Hope, T. J., and Wahl, G. M. (1999) A leucine-rich nuclear export
signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J.
18, 1660–1672.
|
| |
| 17. |
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature
387, 296–299.
|
| |
| 18. |
Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Regulation of p53 stability by Mdm2. Nature
387, 299–303.
|
| |
| 19. |
Maki, C. G., Huibregtse, J. M., and Howley, P. M. (1996) In vivo ubiquitination and proteasome-mediated degradation of p53.
Cancer Res.
56, 2649–2654.
|
| |
| 20. |
Shirangi, T. R., Zaika, A., and Moll, U. M. (2002) Nuclear degradation of p53 occurs during down-regulation of the p53 response
after DNA damage. FASEB J.
16, 420–422.
|
| |
| 21. |
Honda, R., Tanaka, H., and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett.
420, 25–27.
|
| |
| 22. |
Kubbutat, M. H., Ludwig, R. L., Levine, A. J., and Vousden, K. H. (1999) Analysis of the degradation function of Mdm2. Cell Growth Differ.
10, 87–92.
|
| |
| 23. |
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. (2000) Mdm2 is a RING finger-dependent ubiquitin
protein ligase for itself and p53. J. Biol. Chem.
275, 8945–8951.
|
| |
| 24. |
Grossman, S. R., Perez, M., Kung, A. L., et al. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell
2, 405–415.
|
| |
| 25. |
Bottger, A., Bottger, V., Garcia-Echeverria, C., et al. (1997) Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol.
269, 744–756.
|
| |
| 26. |
Fritsche, M., Haessler, C., and Brandner, G. (1993) Induction of nuclear accumulation of the tumor suppressor protein p53
by DNA-damaging agents. Oncogene
8, 307–318.
|
| |
| 27. |
Ko, L. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev.
10, 1054–1072.
|
| |
| 28. |
Waggoner, S. E., Anderson, S. M., Luce, M. C., Takahashi, H., and Boyd, J. (1996) p53 protein expression and gene analysis
in clear cell adenocarcinoma of the vagina and cervix. Gynecol. Oncol.
60, 339–344.
|
| |
| 29. |
Yewdell, J. W., Gannon, J. V., and Lane, D. P. (1986) Monoclonal antibody analysis of p53 expression in normal and transformed
cells. J. Virol.
59, 444–452.
|
| |
| 30. |
Banks, L., Matlashewski, G., and Crawford, L. (1986) Isolation of human p53 specific monoclonal antibodies and their use in
human p53 expression. Eur. J. Biochem.
159, 529–534.
|
| |
| 31. |
Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. (1992) An immunochemical analysis of the human nuclear phosphoprotein
p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods
151, 237–244.
|
| |
| 32. |
Midgley, C. A., Fisher, C. J., Bartek, J., Vojtesek, B., Lane, D., and Barnes, D. M. (1992) Analysis of p53 expression in
human tumours: an antibody raised against p53 expressed in Escherichia coli. J. Cell Sci.
101, 183–189.
|
| |